Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Symbiomix Therapeutics LLC

symbiomix.com

Latest From Symbiomix Therapeutics LLC

Lupin Results Fail To Cheer But Signal Stabilization Of US Generic Market

Lupin’s management refer to multiple indicators suggesting the US generics segment is stabilizing. But traction for some key launches, delivering on pipeline promise, including in the inhalation space, and resolution of compliance issues could hold the key to lifting investor sentiment.

Commercial Strategy

Lupin Q4 Fails To Cheer But Signals Stabilization Of US Generic Market

Lupin’s management refer to multiple indicators suggesting the US generics segment is stabilizing. But traction for some key launches, delivering on pipeline promise, including in the inhalation space, and resolution of compliance issues could hold the key to lifting investor sentiment.

Commercial Strategy

Lupin's US Generics Turn Corner, Spotlight On Upcoming Launches

A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.
Commercial Strategy

Lupin Paints Better Second Half Riding On Solosec, New US Launch Hopes

Lupin is banking on potential new product introductions and a build-up in sales of Solosec to help drive US growth momentum in the second half of fiscal 2019, but concerns over pipeline weakness persist.
Commercial Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Symbiomix Therapeutics LLC
  • Senior Management
  • David L Stern, CEO
    Robert Jacks, Pres. & CFO
    Joseph L Amprey, MD, PhD, CBO
    Tom Beck, MD, Head, R&D & CMO
    Helen S Pentikis, PhD, CSO
    Taunia Markvicka, PharmD, Chief Commercial Officer
  • Contact Info
  • Symbiomix Therapeutics LLC
    Phone: (609) 722-7250
    105 Lock St.
    Ste. 409
    Newark, NJ 07103
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register